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Glomerular size and charge selectivity in insulin-dependent diabetes
mellitus. The pathogenesis of clinical nephropathy in Type 1 (insulin-
dependent) diabetes was investigated by measuring renal fractional
clearances of albumin, total Igo, IgG4 and (32-microglobulin, four
plasma proteins which differ in size and charge. Seventy patients and
eleven control subjects were studied. In diabetic patients with normal
urinary albumin excretion (<30 mg/24 hr), fractional IgG clearance was
two to three times higher than in control subjects, whereas fractional
clearance of the anionic plasma proteins 1g04 and albumin was similar
to that of control subjects. These alterations indicate an increase in
anionic pore charge within the glomerular basement membrane con-
comitant with an increase in either pore size or impairment of tubular
reabsorption. Diabetic patients, whose urinary albumin excretion has
started to rise (30 to 100 mg/24 hr), had unchanged fractional IgG
compared to patients with normal albumin excretion, while fractional
IgG4 and albumin clearances were increased three- to fourfold; indicat-
ing unchanged glomerular pore size, but a decrease in anionic pore
charge. In patients demonstrating urinary albumin excretion of greater
than 100 mg/24 hr fractional IgG clearance increased to the same extent
as fractional albumin clearance, indicating an increase in large pore
area. Fractional -microglobulin clearances were similar to that of
control subjects in the different patient groups indicating unchanged
tubular reabsorption of proteins. Thus, the increase in large pore area
seen in patients with clinical nephropathy is preceded by loss of anionic
charge in the glomerular basement membrane. It is likely that this loss
of anionic charge is due to loss of heparan sulphate-proteoglycan.
Patients with Type 1 (insulin-dependent) diabetes mellitus
and urinary albumin excretion (UaIbV) of more than 300 mg/24
hr have a poor prognosis [1]. The pathogenesis of albuminuria
is, however, unknown. Neither is it known why only 30 to 40%
of the patients develop this serious complication [21, while the
majority of patients have a normal UaIbV below 30 mg/24 hr
after more than 40 years of diabetes in spite of poor metabolic
regulation [3] and rather severe glomerulosclerosis [4].
In patients with persistently increased UalbV greater than 300
mg124 hr (equivalent to persistent proteinuria), changes in
glomerular pore size have been found simultaneously with
decreasing filtration surface [5, 6] and widened and loosened
epithelial foot processes [7]. Intraglomerular pressure is as-
sumed to be increased since filtration fraction is unchanged in
these patients [8] in spite of decreasing ifitration surface [6] and
Received for publication February 13, 1987
and in revised forms June 29 and August 24, 1987
© 1988 by the International Society of Nephrology
lower oncotic pressure [9]. Loss of sialic acid and heparan
sulphate [10] in glomerular basement membranes (GBM) of
these patients has, together with a preferential urinary excre-
tion rate of albumin over IgG [11], suggested changes in charge
selectivity as well. These functional and structural alterations
together with the rise in systemic blood pressure [12] might
explain the fiftyfold increase of UaIbV in patients with persistent
proteinuria. However, in the very early phase of clinical ne-
phropathy. that is, in Albustix negative patients with elevated
glomerular filtration rate (GFR) and UaIbV in the borderline
between normal and clearly elevated UbV, very little is known
about changes in glomerular permselectivity. Since more
knowledge about these patients might give some insight into the
pathogenesis of clinical nephropathy, we studied the renal
fractional clearance of four endogenous plasma-proteins in
patients with Type 1 (insulin-dependent) diabetes and normal
serum creatinine, who demonstrated a wide range of UaIbV. The
four plasma proteins differed in size and charge and were
albumin (molecular weight [MW] 69,000, Stokes radius 36 A, p1
4.7 to 5.5), total IgG (MW 156,000, Stokes radius 55 A, p1 5.8 to
7.3), IgG4 (MW 156,000, Stokes radius 55 A, p1 5.5 to 6.0) and
-microglobulin (MW 11,800, Stokes radius 16 A, p1 5.8).
Subjects
The patients were selected from the outpatient clinic at the
Steno Memorial Hospital, where most of them have been
followed for many years. They had no history of non-diabetic
renal or cardiac disease and all had a negative bacterial culture
of the urine. No drugs other than insulin were given. All
subjects gave informed consent for participation and the study
was approved by The Regional Scientific Ethical Committee.
The diabetic patients were subdivided into four groups accord-
ing to level of albuminuria identified on the basis of the median
albumin excretion in three 24-hour urine collections performed
at home during periods of normal physical activity. This was
done because of the high (50%) day to day variation of the
24-hour urinary albumin excretion [13]. Eleven healthy non-
diabetic subjects served as controls. These subjects only deliv-
ered one 24-hour urine sample. All subjects were below the age
of SO and all patients had had diabetes for five years or more.
Any ongoing antihypertensive treatment had been discontinued
for eight weeks. The four groups were defined as follows:
Group 1. Eighteen patients with normal urinary albumin
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Table 1. Clinical data
Serum
Duration creati- GFR Retino-
UalbV Sex Age of diabetes HbA1 UalbV nine mi/mm BP pathy
mg/24 h M/F years years % m/24 hr junol/l per I .73m2 mm Hg 0/B/P
Controls <30 5/6 31 1.9 — 5.2 0.1 12 2.1 80 3.0 101 3.6 124 2.4 77 2.4 0
N= 11
Group 1
IDDM <30 10/8 35 2.1 19 1.9 8.3 0.3 16 2.1 76 2.4 111 3.8 131 2.6 84 2.4 15/3/0
N = 18
Group 2
IDDM 30—100 12/10 32 2.0 17 1.2 9.2 0.4 46 4.7 80 2.4 117 4.5 127 2.6 81 1.5 11/11/0
N = 22
Group 3 101—300 11/5 33 2.5 17 1.4 9.4 0.4 230 30 89 3.3 102 4.0 132 2.8 86 1.5 5/9/2
IDDM
N = 16
Group 4
IDDM >300 9/5 31 1.9 19 2.1 9.8 0.4 2932 581 94 8.0 86 8.3 159 5.6 102 2.4 2/5/7
N = 14
Mean SEM are indicated.
Retinopathy is graded in 0, minimal changes or less; B, background retinopathy; P, proliferative retinopathy.
excretion, that is, less than 30 mg/24 hr and with blood pressure
less than 160/95 mm Hg.
Group 2. Twenty-two patients with slightly elevated urinary
albumin excretion in the range of 30 to 100 mg/24 hr, that is,
patients with persistent microalbuminuria. Patients with blood
pressure readings more than 160/95 mm Hg were excluded in
order to avoid contamination with hypertension-induced hyper-
albuminuria [14].
Group 3. Sixteen patients with moderately elevated urinary
albumin excretion in the range of 100 to 300 mg/24 hr. Patients
with blood pressure readings greater than 160/95 mm Hg were
excluded.
Group 4. Fourteen patients with diabetic nephropathy (UbV
>300 mg/24 hr).
The clinical characteristics of patients and control subjects
are shown in Table 1.
Methods
The daily excretion of proteins was calculated on the basis of
a 24-hour urine sample collected at home. Urinary albumin
concentrations, urinary total IgG concentration and urinary
132-microglobulin concentration were measured by an ELISA
assay, interassay variation 8.3%, 9.0%, and 9.2%, respectively
[15—17]. Serum albumin, total IgG and /32-microglobulin were
determined by the same ELISA method after proper dilution of
the sample. Urinary and serum IgG4 were measured by an
immunoradiometric assay in which Maxisorb test tubes (Nunc,
Roskilde, Denmark) were coated with 0.25 ml affinity-purified
antihuman IgG4 (aIgG4) (Janssen Biochemica, 2340 Beerse,
Belgium; list No.: SH164-01-S1), diluted 1:3,000 with 0.01 M
phosphate buffered saline, pH 7.5 (PBS) with 0.01% (wt/vol)
sodium azide. After overnight incubation, the tubes were washed
five times with PBS containing 0.1% (wtlvol) Tween 20 (PBS/tw).
The assay was calibrated by use of appropriate dilutions (1 to
200 ng/ml) of a human reference serum from Central Laboratory
of the Laboratory, Red Cross Blood Transfusion Service (list
No.: HOO-2). Reference serum, patients' sera, and urines were
diluted in an incubation buffer (IB) containing 0.5% (wt/vol)
bovine gamma globulin, 5% (wt/vol) heat inactivated (4- hr;
56°C) normal sheep serum, and 0.5% (wt/vol) Tween 20 in 0.1 M
potassium phosphate buffered saline, pH 7.5. The aIgG4 coated
tubes were incubated for four hours at room temperature with
0.25 ml diluted serum or urine, washed five times with PBS/Tw,
and then incubated overnight at room temperature with about
0.1 Ci '251-labelled aIgG4 (SA about 7 Ci/g) in 0.25 ml lB. After
washing five times with PBS/Tw the tubes were counted for one
minute in a gamma-counter. Sensitivity of the assay was 1 ng
IgG4/ml (in diluted solutions). Specificity and reactivity were
evaluated by incubation with 100 ng/ml, highly-purified IgG
myeloma proteins [18], one of each subclass. No IgG4 was
detectable by incubation with IgG1, IgG2, or IgG3 proteins,
indicating that cross-reactivity was less than 1%. Furthermore,
the specificity of the aIgG4 applied in this assay has been found
by others [19] to be comparable to that of a highly specific
monoclonal anti-IgG4 [18]. Recovery of the IgG4 myeloma
protein was 97%. Interassay coefficient of variation was 7.6%.
Hemoglobin A1 was measured by a chromatographic tech-
nique [20]. The normal range was 4.1 to 6.4%. Blood pressure
was measured with a standard sphygmomanometer on the right
arm after 20 minutes of supine rest on several occasions. The
diastolic blood pressure was recorded when the Korotkoff
sounds disappeared (phase V). Serum creatinine was measured
by a reaction rate method modified to eliminate pseudocre-
atinines. The interassay coefficient of variations was 2.5% [21].
The glomerular filtration rate was measured alter a single
intravenous injection of 5lCrEDTA (at 9 a.m.) by observation
of the plasma disappearance for four hours [22]. The fractional
protein clearance was calculated as Urinary protein excretion/
Serum protein concentration x glomerular filtration rate:
Urinary protein excretion
Serum protein concentration x glomerular filtration rate
All results were corrected for variation in body surface. The
patients eyes were examined by routine ophthalmoscopy through
the dilated pupil by a trained observer.
Standard parametric statistics were applied except for protein
clearances which are not normally distributed, unless logarith-
mically transformed [15]. For these calculations we therefore
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Table 2. Fractional clearance, mean (± SEM, log, normal distribution)
UaIbV
mg/24 hr
Calb/GFR
X l0 'IgG/GFRx l0 CIgG4/GFR<x 1O
Cmicro
globulin!GFR X lQ SI (dIgG/Calb)
Controls <30 163NS 0.65c 080NS 338NS 0.41 010b
N = 11 (1.39—1.90) (0.56—0.74) (0.66—0.96) (2.86—4.00)
IDDM <30 l.80c 153NS 0.85° 431NS 0.88 0.13°
N = 18 (1,52—2.13) (1.30—1.80) (0.58—1.23) (3.54—5.24)
IDDM 30—100 5.46 1.75 3.19° 430NS 0.38 0.0?
N = 22 (4.75—6.26) (1.50—2.03) (2.65—3.85) (3.85—4.79)
IDDM 101—300 32.14 6.75° 13.58a 596NS 0.23 003NS
N = 16 (27.86—37.07) (5.69—8.00) (8.02—23.01) (4.79—7.41)
IDDM >300 477 72.95 62.66 13.40 0.16 0.02
N = 14 (330—693) (48.75—109.14) (41.11—95.50) (8.34—21.53)
SI: selectivity index (clearance of IgG/clearance of albumin), mean SEM.
x only 10, 10, 5, 5, and 10 cases were analyzed.
NS, a, b, and care: non-significant (2P >0,05), 2P <0.05, 2P <0.02, 2P <0.01, respectively, in comparison to the next group in the same cot-
umn.
applied parametric statistics only after log transformations.
Comparisons between groups were—after proper logarithm
transformation—performed by t-tests after demonstrating sig-
nificant differences between groups by ANOVA (Kruskall-
Wallis).
Results
The groups of patients were fairly well matched according to
sex, age, diabetes duration, diabetes regulation, and blood
pressure with the exception of patients in group 4 (clinical
nephropathy) who had higher HbA1, creatinine, and blood
pressure compared with the other groups. The glomerular
filtration rate (GFR) was significantly increased in most diabetic
patients except in patients with clinical nephropathy (UaibV
>300 mg!24 hr), who demonstrated a wide range of GFR (41 to
152 mllmin/l.73 m2; Table 1).
In patients with normal UaIbV (group 1) fractional IgG clear-
ance was significantly increased, whereas the fractional albu-
min clearance and the fractional clearance of anionic IgG4 were
similar to that of controls (Table 2). Fractional IgG clearance
was not correlated to age, diabetes duration, HbA1, or GFR.
Since the fractional IgG clearance was increased and fractional
albumin and IgG4 clearances were unchanged, the relative IgG
clearance (selectivity index SI = IgG clearance/albumin clear-
ance) was significantly elevated (2P = 0.011) (Fig. 1). The
increase in IgG/IgG4 clearance did not reach statistical signifi-
cance.
In patients with slightly elevated UalbV (30 to 100 mg/24 hr),
(group 2) fractional IgG clearance was similar to that of diabetic
patients with normal UaibV. However, fractional IgG4 clearance
was now increased three- to fourfold in comparison with
controls or patients demonstrating normal UaIbV. This increase
was of the same magnitude as the increase in fractional albumin
clearance. These changes resulted in a significant decrease in
selectivity index, SI compared to diabetics with normal UalbV.
The IgG/IgG4 clearance decreased too, but again without reach-
ing statistical significance.
In patients with more marked microalbuminuria (100 to 300
mg/24 hr) (group 3) the fractional clearance of IgG was in-
creased fourfold compared with diabetics of groups 1 and 2 and
to similar degree as the fractional albumin clearance. Also,
fractional IgG4 clearance was further increased. A significant
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correlation between fractional albumin and fractional IgG clear-
ances was seen in this group of patients alone and also when
patients with clinical nephropathy (group 4) were included (r =
0.952, 2 P < 0.01, N = 30) (Fig, 2). A further decrease in SI was
seen in groups 3 and 4 (Fig. 1), whereas no further change in
IgG/IgG4 clearances could be demonstrated,
The urinary excretion of /32-microglobulin was higher in
diabetic patients comptred to controls, but the difference did
not reach statistical significance and the fractional clearance of
j32-microglobulins was similar in all groups (Table 2). Only in
patients with GFR below 80 mi/mm/I .73 m2 was the fractional
/32-microglobulin clearance clearly increased.
Discussion
All patients suffered from Type 1 diabetes. The serum sam-
ples were taken after the patient had relaxed for at least 30
minutes in the supine position to avoid hemoconcentration and
increase of plasma protein in the upright position. Urine sam-
ples were kept at —20°C until analysis of the whole material,
which was performed in random order within a few days.
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Fig. 1. Selectivity index (clearance of lgG/clearance of albumin) in 11
controls and 70 patients with Type I (insulin-dependent) diabetes and
dWerent degrees of urinary albumin excretion (Ua/bV).
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Fig. 2. Albumin and !gG clearance in 11 control subjects and 70
patients with Type 1 (insulin-dependent) diabetes and different degrees
of urinary albumin excretion. (Group designation as in Fig. 1.) Log
transformation was performed before the calculation of regression.
Symbols are: (•)controls, r = 0.864, y = —0.16 + 0.81x, 2P < 0.Ol;(*)
IDDM, UalbV <30 mg124 hr, r 0.510, y = 0.41 + 0.61x, 2P < 0.05; (A)
IDDM, U,V 30 to 100 mg/24 hr, r = 0.578, y = 0.14 + 0.66x, 2P <
0.01; (0) IDDM, U,V 101 to 300 mg/24 hr, r = 0.663, y = —0.13 +
0.78x, 2P < 0.01; (U) IDDM, UbV >300 mg/24 hr, r =0.947, y =
—0.97 + l.04x, 2P < 0.01.
IgG4 was only analyzed in 40 patients due to lack of sufficient
specific antiserum. Ten controls and 10 + 5 + 5 + 10 diabetic
patients from group 1 to group 4, respectively, were analyzed
after random selection. Since the concentration of anionic IgG4
in plasma and urine was only 3 to 4% of the total IgG
concentration, total IgG was taken as representative of un-
charged IgG. Glomerular filtration of plasma protein is re-
stricted by glomerular basement membrane pore size and
charge [23]. From experiments with dextrans [24], the mean
glomerular pore radius is calculated to be of the same size as
pores of fenestrated capillaries, which is about 55 A [25]. A
lognormal distribution of glomerular pore size has been dem-
onstrated to fit well with experimental data [26]. The surface of
the pores is, as in other endothelial pores, covered with highly
anionic heparan sulphate [25], thus contributing to the charge
selectivity of the GBM [27]. The regularly arranged anionic
sites seen in the lamina rara of GBM from animals [28] and man
[29, 30] might be equivalent to pores in the basement mem-
brane. The fractional IgG clearance can be assumed to reflect
either size non-selective pores (shunts) of about 100 A Stokes
radius or the very small fraction of relatively large pores (>55
A) within the lognormal pore distribution [26]. Since our
experimental findings seem to fit better to lognormal pore
distribution, we will base our discussion on this model.
In diabetic patients with normal UalbV we unexpectedly
found fractional IgG clearance to be significantly increased,
indicating an increased large pore area or impaired tubular
reabsorption. The latter assumption is supported by fractional
dextran clearance studies demonstrating that pore size distri-
bution in uncomplicated diabetic patients is identical with that
of control subjects [5, 31, 32]. However, due to the very low
fraction of large pores and the variance of such measurements,
an increase of the large pore area can not be totally excluded
from these experiments. The results of fractional 132-microglo-
bulin clearances in our patients also make impaired tubular
reabsorption less likely (Table 2). Increased fractional IgG
clearance has not been demonstrated earlier in normoalbumi-
nuric diabetic patients. It might be correlated to increased
intraglomerular pressure. The increase of fractional IgG clear-
ance was not accompanied by a similar increase of fractional
albumin clearance. Plasma albumin molecules have a signifi-
cantly lower Stokes radius than IgG molecules (36 and 55 A,
respectively) and would therefore be able to pass much easier
through pores of increased diameter than IgG if not retropulsive
forces between the negative charge of the albumin molecule and
the glomerular membrane inhibit the passage. The fact that the
fractional albumin clearance was not increased in diabetic
patients with normal UalbV thus indicates that the increased
pore area in these patients is counterbalanced by increased
anionic pore charge. This assumption is supported by the
unchanged fractional clearance of anionic IgG4 (Table 2). Since
IgG4 has the same molecular size as neutral IgG, the lack of a
threefold iflcrease of fractional IgG4 can only be explained by
an increase of retropulsive forces between the glomerular pore
and IgG4 molecules.
Increased restriction to the passage of anionic macromol-
ecules has also been demonstrated in rats after three months of
diabetes [33]. The decreased passage of anionic dextran mac-
romolecules in this experiment was attributed to an increased
negative charge density in the filtration barrier secondary to
compositional alterations of the glomerular basement mem-
brane [33]. The cause of increased anionic pore charge in
diabetic patients with normal UaibV might be due to non-
enzymatic glycation of GBM [34—36] or clogging of the GBM
with anionic plasma proteins [37—41]. Our finding of increased
fractional IgG clearance, but unchanged albumin and IgG4
clearance in diabetic patients with normal UaIbV, can thus best
be explained by a more negative pore charge in combination
with either increased pore size or impaired tubular reabsorp-
tion.
In patients with slightly increased UaIbV (30 to 100 mg124 hr)
other changes in pore charge seem to appear. In spite of
unchanged fractional IgG clearance, the fractional albumin
clearance was increased threefold. Two explanations seem to
be possible: (1) formation of new electroneutral pores of less
than 55 A Stokes radius making it possible for albumin mole-
cules to pass through, whereas IgG molecules cannot pass [5,
42]; or (2) loss of anionic charge within the existing pores of
diabetic patients. Both possibilities would fit our recent finding
of a decreased albumin/glycated albumin clearance ratio in
these patients [36]. However, the highly significant increase in
fractional IgG4 clearance in these patients is not consistent with
the formation of new small neutral pores. We therefore believe
that patients with slightly increased UaIbV are characterized by
reduced anionic glomerular pore charge in comparison with
diabetic patients with normal UaIbV. Since HbA1 was similar as
in diabetic patients with normal UaIbV, reduced non-enzymatic
glycation of GBM as a cause of reduced anionic charge is
unlikely. Also, loss of anionic plasma protein deposits in the
GBM of these patients is unlikely, since the amount of anionic
.
UI ••.
U
0
0 •
0 000
00 U0
0.1 1.0 10 100
C11,, I/min/1.73
104 Deckert et a!: Glomerular permselectivity in diabetes
plasma protein deposits within the GBM does not seem to be
less in patients with diabetic nephropathy [34, 391.We therefore
believe that the decrease in anionic charge is due to loss of other
anionic substances in the basement membrane such as acidic
amino acid residues, sialic acid or heparan sulphate-proteo-
glycan. The concentration of acidic amino acids, however, has
been found to be unchanged in human GBM from patients with
diabetic nephropathy [10]. Only the content of sialic acid 1101
and heparan sulphate [34, 43] has been shown to be reduced.
Since sialic acid is present only on epithelial and endothelial cell
surfaces, but not within the GBM [44], the decrease in anionic
charge found in our studies is probably due to loss of heparan
sulphate and/or decreased sulfation of heparan-sulfate-proteo-
glycan. It has been demonstrated earlier that loss of heparan
sulphate in GBM results in albuminuria [45]. Furthermore, loss
of anionic sites in diabetic patients with albuminuria has re-
cently been demonstrated [30, 46]. It has also been shown
several times that incorporation of SO4— into heparan sulphate
of the GBM of diabetic animals is decreased [47—51] and that the
concentration of heparan sulphate in GBM from diabetic pa-
tients might be decreased [34, 43]. Therefore it seems most
likely that the initial increase of UalbV in insulin-dependent
diabetic patients is caused by a reduction in the content or
suiphation of heparan sulphate within the pores of the GBM and
not by the formation of new pores.
In patients with more advanced microalbuminuria (U5IbV 100
to 300 mg/24 hr, group 3), fractional IgG clearance was in-
creased fourfold compared to patients of group 2. It is not
possible from our studies to determine whether this increase in
fractional IgG clearance was due to the formation of new large
pores [26] or modification of original pores. We assume that loss
of heparan sulphate-proteoglycan or decreased sulfation of
heparan sulphate in basement membrane pores might well lead
to microstructural disruption due to decreased crosslink forma-
tion to fibronection and collagen IV [45, 52—56]. The unchanged
IgG/IgG4 clearance in these patients compared to patients with
less UaIbV indicates that changes in pore size now dominate
changes in charge.
Our findings in patients with UajbV greater than 300 mg124 hr
do not point to further qualitative changes in the GBM, but pore
size or number are probably increasing further as indicated by
the proportional increase of fractional IgG and albumin clear-
ances (Fig, 2). The mean fractional clearance of /32-microglo-
bulin was slightly higher in diabetic patients compared to
controls. However, the difference between these groups was
not statistically significant. Only in patients with persistent
proteinuria and GFR less than 80 mllminll .73 m was plasma
J32-microglobulin elevated, indicating reduced kidney function.
In these patients also the urinary 132-microglobulin excretion
was high and above the normal range.
Our findings in diabetic patients with increased UlbV are in
close agreement with earlier findings by others [11, 321. How-
ever, since diabetic patients with normal UbV were not studied
by these groups and clearance studies with IgG4 to our knowl-
edge have never been done before, these groups were unable to
elucidate the difference in glomerular charge and size selectivity
between controls and diabetic patients without and with slightly
increased UaIbV.
Our study indicated changes in charge selectivity of the
glomerular membrane in diabetic patients with normal UalbV.
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Furthermore, we demonstrated that the increase in large pore
area seen in patients with albuminuria is preceded by loss of
charge selectivity (Fig. 3). We feel these alterations are likely
due to loss of heparan sulphate in the GBM. The cause of the
decrease in sulphation or loss of heparan sulphate is not fully
understood but could be linked to genetic differences in the
activity of N-deacetylase—the key enzyme in N-sulfation of
heparan sulfate.
?eprin: requests to Torsten Decker!, M.D., Steno Memorial Hospi-
tal, Niels Steensensvel 2, DK-2820 Gentofte, Denmark,
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